Developer docs
API playgroundTry for free, no card

Search company profiles

CellPhire

Full company profile

uuid0000ymu

Namestring
CellPhire
Legal namestring
Cellphire, Inc.
Websiteurl
cellphire.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
platelet-derived therapeutics, cryopreserved platelets, freeze-dried hemostat, hemorrhage treatment, allogeneic cellular biologics
Industry6 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAB
Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAJ
Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAHAG
Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Blood and Organ Banks621991
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Platelet-Derived Biologic Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Revenue
TypeOne Time License
Description

As a pre-revenue clinical-stage biotechnology company, Cellphire does not yet generate product revenue. The company is advancing its platelet-derived biologic pipeline toward regulatory approval (BLA). CLPH-511 targets BLA filing in 2026. Revenue will ultimately come from commercial sales of CLPH-511 (cryopreserved platelets) and FPH platform products (CLPH-211, CLPH-251) upon FDA approval. The company also operates a veterinary subsidiary BodeVet with a commercially available canine product (StablePlate RX).

cellphire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Pre-commercial / Investigational Products
ModelOther
Notes

Products are investigational and not yet commercially available. No public pricing disclosed.

cellphire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BodeVet
Description

Veterinary subsidiary developing and commercializing transfusion medicine therapies for companion animals including StablePlate RX Canine freeze-dried platelet product for dogs.

cellphire.com
+1 more record
Core offering1 text field

Cellphire develops stabilized, allogeneic, platelet-derived cellular therapeutics through two proprietary platforms: CLPH-511 cryopreserved platelets with a 5-year frozen shelf life, and the FPH/Thrombosomes freeze-dried platelet-derived hemostat with 3+ year room temperature stability. Both products are manufactured from pooled, irradiated, leukocyte-reduced Group O donor apheresis platelets. The company also operates a veterinary subsidiary (BodeVet) commercializing a canine freeze-dried platelet product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CRYPTICS trial met primary efficacy endpoint: 24-hour chest tube drainage difference in LS Means was 142.0 mL (95.576% CI lower than non-inferiority margin); p-value < 0.00965; trial stopped early for efficacy after >150 subjects.
+4 more records
Product overview1 text field

Cellphire Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation allogeneic, stabilized platelet-derived cellular therapeutics. The company operates two core technology platforms: Cryopreserved Platelets (CLPH-511) with 5-year frozen shelf life and the FPH (Freeze-dried Platelet-derived Hemostat) platform (CLPH-211, CLPH-251, CLPH-291) with 3+ year room temperature stability. CLPH-511 is the lead product in Phase 2/3 clinical trials for acute hemorrhage, while CLPH-211 is advancing in Phase 2 studies for perioperative bleeding. A discovery-stage drug delivery platform (CLPH-701) explores loading therapeutic molecules into stabilized platelets. The company also operates BodeVet, a veterinary subsidiary commercializing freeze-dried platelet products for animals.

Product and service6 records
1CLPH-511 (Cryopreserved Platelets / CPP)
CategoryCore Product - Cryopreserved Platelet Biologic
Description

CLPH-511 is a frozen, activated platelet product for IV use with a 5-year shelf life stored at ≤-65°C. Manufactured from pooled, irradiated, leukocyte-reduced apheresis platelets from up to 10 Group O donors, concentrated with DMSO cryoprotectant before freezing. Thawing and resuspension takes approximately 15 minutes. It is being developed for acute hemorrhage as an alternative to conventional liquid stored platelets when not available or in short supply. CRYPTICS Phase 2/3 trial was stopped early for efficacy after 150+ subjects.

2CLPH-211 (FPH / Thrombosomes)
CategoryCore Product - Freeze-Dried Platelet Hemostatic Biologic
Description

CLPH-211 (marketed as Thrombosomes) is a freeze-dried platelet-derived hemostatic agent with 3+ year room temperature shelf life. Manufactured by pooling platelets from 10 Group O donors, removing plasma, loading trehalose as a stabilizer, and freeze-drying. Rehydrated with sterile water in minutes for systemic hemostatic use in uncontrolled perioperative bleeding, either alone or as adjunct therapy. Heat-treated for pathogen reduction with 70+ human exposures and positive safety data.

3CLPH-251 (FPH for TBI/ICH)
CategoryPipeline Product - Freeze-Dried Platelet Biologic
Description

CLPH-251 is an FPH platform product in pre-IND stage for treatment of Traumatic Brain Injury (TBI) with acute hemorrhage and spontaneous Acute Intracerebral Hemorrhage (sICH). It has potential to stop hemorrhage, prevent hematoma volume expansion, and reduce secondary injury. Approximately 1.4 million individuals incur TBI in the US annually with 90,000 experiencing long-term disabilities.

4CLPH-291 (FPH Pipeline Product)
CategoryPipeline Product - Freeze-Dried Platelet Biologic
Description

CLPH-291 is a freeze-dried platelet-derived hemostatic product in development as part of the FPH platform family. It is positioned as a pipeline product leveraging the company's core freeze-drying and trehalose stabilization technology.

5CLPH-701 (Platelet-Enabled Drug Delivery)
CategoryPlatform Technology - Drug Delivery
Description

CLPH-701 is a discovery-stage platform technology for loading and stabilizing different types of biologic molecules into platelets for targeted drug delivery. Applications include oncology, tumor metastasis, cardiac ischemia, RNA/miRNA delivery, and innate immunity. The technology uses the company's proprietary platelet stabilization methods to create drug-loaded platelet products.

6StablePlate RX Canine
CategoryVeterinary Product - Freeze-Dried Platelet
Description

StablePlate RX Canine is a commercially available canine freeze-dried platelet product with demonstrated efficacy in stopping bleeding in dogs. Developed and marketed by BodeVet, Cellphire's veterinary subsidiary, with expansion underway to support equine patients and exotic animals such as elephants.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-13
Description

Strategic partnership with Vitalant, one of the nation's largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets (CPP). Vitalant serves as a critical supplier for Cellphire's product development and clinical manufacturing.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Consortium partner supporting medical technology development for military applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator conducting preclinical research demonstrating vascular repair and neuroprotective effects of platelet-derived biologic in traumatic brain injury. Study published in Blood journal (April 2026). Joint research on Ang1-Tie2 signaling pathway activation.

4Rigshospitalet Copenhagen University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Principal investigator-initiated trial site for Thrombosomes (FPH) in Acute Thoracic Aortic Dissections (TTAD). Dr. Jakob Stensballe and Dr. Annette Ulrich led enrollment of 41 patients, completing ahead of schedule. Supported by Danish clinical research infrastructure.

cellphire.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner in Cellphire's network of research universities advancing development of stabilized cellular therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner and clinical trial site (University of Maryland Medical Center) participating in CRYPTICS Phase 2/3 study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site (Johns Hopkins Hospital) for CRYPTICS study; Dr. Glenn Whitman presented CRYPTICS topline data at 2025 AABB Annual Meeting. Advisory board member Dr. Glen Whitman serves as Director of CV Surgical ICU and Professor of Cardiac Surgery.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific advisor Dr. Jose A. Cancelas serves as Executive Director at Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber, providing scientific guidance on transfusion medicine and cell therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner with MedStar Georgetown University Hospital serving as a clinical trial site for Thrombosomes Phase 2 study.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Thrombosomes Phase 2 study in bleeding thrombocytopenic patients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Thrombosomes Phase 2 study.

12Vanderbilt Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial site for Thrombosomes Phase 2 study and CRYPTICS Phase 2/3 study.

cellphire.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaborator in Cellphire's research network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Veterinary subsidiary of Cellphire developing and commercializing companion animal transfusion medicine products including StablePlate RX Canine. Expanding to equine and exotic animal applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Velico is developing spray-dried plasma products for hemostatic and trauma use, including products targeting emergency and military settings. It is a direct peer in the stabilized/lyophilized blood product space where shelf life and rapid reconstitution are critical.

TypeEmerging player
Description

Medcura develops hemostatic products for surgical, trauma, and consumer applications using proprietary biopolymer technology. It is an emerging player in the bleeding management space with overlapping surgical and trauma use cases.

TypeEmerging player
Description

Cresilon develops hemostatic gel technology (Veti-Gel) for rapid bleeding control in trauma, surgical, and veterinary settings. It is an emerging player in the broader hemostasis market with overlapping customer segments (trauma, surgical, veterinary) and product positioning.

TypeBroad incumbent
Description

Grifols is a global leader in plasma-derived therapies and blood products, including platelet-related fractionation and transfusion products. As a broad incumbent, it has the scale, regulatory relationships, and commercial reach that any successful stabilized platelet therapy would eventually compete against.

TypeEmerging player
Description

Lineage Cell Therapeutics is an allogeneic cell therapy developer with a multi-platform pipeline addressing ophthalmology, oncology, and neurological indications. It is an emerging player in the allogeneic, off-the-shelf cell therapy space that shares the platform-based, multi-indication approach that defines Cellphire's platelet-derived pipeline.

TypeBroad incumbent
Description

Terumo BCT is a global leader in blood component collection, processing, and storage technologies, including platelet apheresis systems. It is a broad incumbent supplying the equipment and consumables underpinning the platelet supply chain that Cellphire's technology ultimately serves.

TypeDirect peer
Description

Cerus develops INTERCEPT, a pathogen-reduction system for platelets and other blood components. As a direct peer in the platelet safety/supply space, Cerus is highly comparable to Cellphire in addressing limitations of conventional platelet storage and transfusion safety.

TypeBroad incumbent
Description

Octapharma is a major human protein products manufacturer with a portfolio that includes coagulation and hemostasis products. It is a broad incumbent in the blood-derived therapeutics space with overlapping indications (perioperative bleeding, hemophilia).

9Pluristem Therapeutics
TypeEmerging player
Description

Pluristem is developing off-the-shelf allogeneic cell therapy products from placental cells for hematology, inflammation, and ischemia indications. It is an emerging player in the allogeneic cell therapy space with a similar platform-approach to addressing multiple indications from a single manufacturing process.

TypeBroad incumbent
Description

CSL Behring is a global leader in plasma-derived and recombinant therapeutic proteins, including products for hemostasis, coagulation, and critical care. It is a broad incumbent with deep relationships in hospital transfusion medicine and trauma care.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellPhire

Platelet-Derived Biologic Therapeuticscellphire.com

CellPhire firmographics

Firmographics
Name
CellPhire
Legal name
Cellphire, Inc.
Website
https://cellphire.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

CellPhire industry classification

Industry
Product category
Platelet-Derived Biologic Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAMANAB
Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAJ
Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAMANAA
Stem Cell Therapies (Autologous & Allogeneic)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAHAG
Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin)

Keywords

  • Platelet-derived therapeutics
  • Cryopreserved platelets
  • Freeze-dried hemostat
  • Hemorrhage treatment
  • Allogeneic cellular biologics

Where CellPhire is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CellPhire business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Biopharmaceutical Product Revenue: As a pre-revenue clinical-stage biotechnology company, Cellphire does not yet generate product revenue. The company is advancing its platelet-derived biologic pipeline toward regulatory approval (BLA). CLPH-511 targets BLA filing in 2026. Revenue will ultimately come from commercial sales of CLPH-511 (cryopreserved platelets) and FPH platform products (CLPH-211, CLPH-251) upon FDA approval. The company also operates a veterinary subsidiary BodeVet with a commercially available canine product (StablePlate RX).

Pricing tiers

ModelBillingPrice
Other—Pre-commercial / Investigational Products

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

CellPhire product offering

Product offering

Core offering

Cellphire develops stabilized, allogeneic, platelet-derived cellular therapeutics through two proprietary platforms: CLPH-511 cryopreserved platelets with a 5-year frozen shelf life, and the FPH/Thrombosomes freeze-dried platelet-derived hemostat with 3+ year room temperature stability. Both products are manufactured from pooled, irradiated, leukocyte-reduced Group O donor apheresis platelets. The company also operates a veterinary subsidiary (BodeVet) commercializing a canine freeze-dried platelet product.

Product overview

Cellphire Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation allogeneic, stabilized platelet-derived cellular therapeutics. The company operates two core technology platforms: Cryopreserved Platelets (CLPH-511) with 5-year frozen shelf life and the FPH (Freeze-dried Platelet-derived Hemostat) platform (CLPH-211, CLPH-251, CLPH-291) with 3+ year room temperature stability. CLPH-511 is the lead product in Phase 2/3 clinical trials for acute hemorrhage, while CLPH-211 is advancing in Phase 2 studies for perioperative bleeding. A discovery-stage drug delivery platform (CLPH-701) explores loading therapeutic molecules into stabilized platelets. The company also operates BodeVet, a veterinary subsidiary commercializing freeze-dried platelet products for animals.

Differentiator

Problem solved

Functional benefit

Brands

  • BodeVet: Veterinary subsidiary developing and commercializing transfusion medicine therapies for companion animals including StablePlate RX Canine freeze-dried platelet product for dogs.
  • Thrombosomes

Products and services

  • CLPH-511 (Cryopreserved Platelets / CPP) CLPH-511 is a frozen, activated platelet product for IV use with a 5-year shelf life stored at ≤-65°C. Manufactured from pooled, irradiated, leukocyte-reduced apheresis platelets from up to 10 Group O donors, concentrated with DMSO cryoprotectant before freezing. Thawing and resuspension takes approximately 15 minutes. It is being developed for acute hemorrhage as an alternative to conventional liquid stored platelets when not available or in short supply. CRYPTICS Phase 2/3 trial was stopped early for efficacy after 150+ subjects.
  • CLPH-211 (FPH / Thrombosomes) CLPH-211 (marketed as Thrombosomes) is a freeze-dried platelet-derived hemostatic agent with 3+ year room temperature shelf life. Manufactured by pooling platelets from 10 Group O donors, removing plasma, loading trehalose as a stabilizer, and freeze-drying. Rehydrated with sterile water in minutes for systemic hemostatic use in uncontrolled perioperative bleeding, either alone or as adjunct therapy. Heat-treated for pathogen reduction with 70+ human exposures and positive safety data.
  • CLPH-251 (FPH for TBI/ICH) CLPH-251 is an FPH platform product in pre-IND stage for treatment of Traumatic Brain Injury (TBI) with acute hemorrhage and spontaneous Acute Intracerebral Hemorrhage (sICH). It has potential to stop hemorrhage, prevent hematoma volume expansion, and reduce secondary injury. Approximately 1.4 million individuals incur TBI in the US annually with 90,000 experiencing long-term disabilities.
  • CLPH-291 (FPH Pipeline Product) CLPH-291 is a freeze-dried platelet-derived hemostatic product in development as part of the FPH platform family. It is positioned as a pipeline product leveraging the company's core freeze-drying and trehalose stabilization technology.
  • CLPH-701 (Platelet-Enabled Drug Delivery) CLPH-701 is a discovery-stage platform technology for loading and stabilizing different types of biologic molecules into platelets for targeted drug delivery. Applications include oncology, tumor metastasis, cardiac ischemia, RNA/miRNA delivery, and innate immunity. The technology uses the company's proprietary platelet stabilization methods to create drug-loaded platelet products.
  • StablePlate RX Canine StablePlate RX Canine is a commercially available canine freeze-dried platelet product with demonstrated efficacy in stopping bleeding in dogs. Developed and marketed by BodeVet, Cellphire's veterinary subsidiary, with expansion underway to support equine patients and exotic animals such as elephants.

Quantifiable outcome

  • CRYPTICS trial met primary efficacy endpoint: 24-hour chest tube drainage difference in LS Means was 142.0 mL (95.576% CI lower than non-inferiority margin); p-value < 0.00965; trial stopped early for efficacy after >150 subjects.
  • +4 more outcomes

Companies that use CellPhire

Customer profile

Named customers10 records

Segments6 records

Ideal customer profiles4 records

CellPhire technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

CellPhire partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • VitalantcoreStrategic or Co-development Partner · 13 May 2024Strategic partnership with Vitalant, one of the nation's largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets (CPP). Vitalant serves as a critical supplier for Cellphire's product development and clinical manufacturing.
  • Medical Technology Enterprise Consortium (MTEC)minorStrategic or Co-development PartnerConsortium partner supporting medical technology development for military applications.
  • University of California San Francisco (UCSF)coreStrategic or Co-development PartnerAcademic collaborator conducting preclinical research demonstrating vascular repair and neuroprotective effects of platelet-derived biologic in traumatic brain injury. Study published in Blood journal (April 2026). Joint research on Ang1-Tie2 signaling pathway activation.
  • Rigshospitalet Copenhagen University HospitalcoreStrategic or Co-development PartnerPrincipal investigator-initiated trial site for Thrombosomes (FPH) in Acute Thoracic Aortic Dissections (TTAD). Dr. Jakob Stensballe and Dr. Annette Ulrich led enrollment of 41 patients, completing ahead of schedule. Supported by Danish clinical research infrastructure.
  • Weill Cornell MedicineminorStrategic or Co-development PartnerAcademic partner in Cellphire's network of research universities advancing development of stabilized cellular therapies.
  • University of MarylandminorStrategic or Co-development PartnerAcademic partner and clinical trial site (University of Maryland Medical Center) participating in CRYPTICS Phase 2/3 study.
  • Johns Hopkins UniversitycoreStrategic or Co-development PartnerClinical trial site (Johns Hopkins Hospital) for CRYPTICS study; Dr. Glenn Whitman presented CRYPTICS topline data at 2025 AABB Annual Meeting. Advisory board member Dr. Glen Whitman serves as Director of CV Surgical ICU and Professor of Cardiac Surgery.
  • Dana-Farber Cancer Institute / Harvard Medical SchoolminorStrategic or Co-development PartnerScientific advisor Dr. Jose A. Cancelas serves as Executive Director at Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber, providing scientific guidance on transfusion medicine and cell therapies.
  • Georgetown UniversityminorStrategic or Co-development PartnerAcademic partner with MedStar Georgetown University Hospital serving as a clinical trial site for Thrombosomes Phase 2 study.
  • MD Anderson Cancer CenterminorStrategic or Co-development PartnerClinical trial site for Thrombosomes Phase 2 study in bleeding thrombocytopenic patients.
  • City of HopeminorStrategic or Co-development PartnerClinical trial site for Thrombosomes Phase 2 study.
  • Vanderbilt Medical CenterminorStrategic or Co-development PartnerClinical trial site for Thrombosomes Phase 2 study and CRYPTICS Phase 2/3 study.
  • Kansas State UniversityminorStrategic or Co-development PartnerAcademic collaborator in Cellphire's research network.
  • BodeVetminorStrategic or Co-development PartnerVeterinary subsidiary of Cellphire developing and commercializing companion animal transfusion medicine products including StablePlate RX Canine. Expanding to equine and exotic animal applications.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

CellPhire competitors and assessment

Company assessment

Direct peers

  • Velico Medical: Velico is developing spray-dried plasma products for hemostatic and trauma use, including products targeting emergency and military settings. It is a direct peer in the stabilized/lyophilized blood product space where shelf life and rapid reconstitution are critical.
  • Cerus Corporation: Cerus develops INTERCEPT, a pathogen-reduction system for platelets and other blood components. As a direct peer in the platelet safety/supply space, Cerus is highly comparable to Cellphire in addressing limitations of conventional platelet storage and transfusion safety.

Emerging players

  • Medcura: Medcura develops hemostatic products for surgical, trauma, and consumer applications using proprietary biopolymer technology. It is an emerging player in the bleeding management space with overlapping surgical and trauma use cases.
  • Cresilon: Cresilon develops hemostatic gel technology (Veti-Gel) for rapid bleeding control in trauma, surgical, and veterinary settings. It is an emerging player in the broader hemostasis market with overlapping customer segments (trauma, surgical, veterinary) and product positioning.
  • Lineage Cell Therapeutics: Lineage Cell Therapeutics is an allogeneic cell therapy developer with a multi-platform pipeline addressing ophthalmology, oncology, and neurological indications. It is an emerging player in the allogeneic, off-the-shelf cell therapy space that shares the platform-based, multi-indication approach that defines Cellphire's platelet-derived pipeline.
  • Pluristem Therapeutics: Pluristem is developing off-the-shelf allogeneic cell therapy products from placental cells for hematology, inflammation, and ischemia indications. It is an emerging player in the allogeneic cell therapy space with a similar platform-approach to addressing multiple indications from a single manufacturing process.

Broad incumbents

  • Grifols: Grifols is a global leader in plasma-derived therapies and blood products, including platelet-related fractionation and transfusion products. As a broad incumbent, it has the scale, regulatory relationships, and commercial reach that any successful stabilized platelet therapy would eventually compete against.
  • Terumo BCT: Terumo BCT is a global leader in blood component collection, processing, and storage technologies, including platelet apheresis systems. It is a broad incumbent supplying the equipment and consumables underpinning the platelet supply chain that Cellphire's technology ultimately serves.
  • Octapharma: Octapharma is a major human protein products manufacturer with a portfolio that includes coagulation and hemostasis products. It is a broad incumbent in the blood-derived therapeutics space with overlapping indications (perioperative bleeding, hemophilia).
  • CSL Behring: CSL Behring is a global leader in plasma-derived and recombinant therapeutic proteins, including products for hemostasis, coagulation, and critical care. It is a broad incumbent with deep relationships in hospital transfusion medicine and trauma care.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CellPhire social profiles

Digital presence

CellPhire financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellPhire leadership team

Management profile

Number of profiles

Profiles9 records

CellPhire subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CellPhire funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellPhire M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellPhire

What does CellPhire do?

Cellphire develops stabilized, allogeneic, platelet-derived cellular therapeutics through two proprietary platforms: CLPH-511 cryopreserved platelets with a 5-year frozen shelf life, and the FPH/Thrombosomes freeze-dried platelet-derived hemostat with 3+ year room temperature stability. Both products are manufactured from pooled, irradiated, leukocyte-reduced Group O donor apheresis platelets. The company also operates a veterinary subsidiary (BodeVet) commercializing a canine freeze-dried platelet product.

Is CellPhire a public or private company?

CellPhire is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellPhire founded?

CellPhire was founded in 2014. It employs 11 to 50 people.

Where is CellPhire based?

CellPhire is headquartered in Rockville, United States, in the North America region.

How does CellPhire make money?

One revenue line is on record: biopharmaceutical Product Revenue.

Who are CellPhire's main competitors?

Direct peers on record are Velico Medical and Cerus Corporation. Emerging players are Medcura, Cresilon, Lineage Cell Therapeutics and Pluristem Therapeutics. Broad incumbents are Grifols, Terumo BCT, Octapharma and CSL Behring.

Does CellPhire have an API?

No public API is recorded for CellPhire.

What industry is CellPhire in?

CellPhire's product category is Platelet-Derived Biologic Therapeutics. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAMANAB, Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DCellphire, Inc., a Delaware-incorporated biotechnology company headquartered in Rockville, Maryland, filed a Form D notice with the SEC on December 11, 2025, for an exempt offering of debt and equity securities valued at $3,000,000. The offering, which claimed exemptions under Rule 506(b) and Rule 506(c) of the Securities Act, completed with 19 investors after its first sale on November 26, 2025, and no proceeds were allocated to payments for executive officers, directors, or promoters.SecSEC FORM DCellphire, Inc. filed a Form D with the SEC to announce an exempt offering of securities under Rule 506(b), initiated on September 19, 2023. The company has raised $2 million of an $8 million total target, with a minimum investment requirement of $100,000 per accredited investor.BioSpaceCellphire Therapeutics Appoints Pamela B. Conley to its Board of DirectorsCellphire Therapeutics appointed Pamela B. Conley, Ph.D., to its board of directors. Conley previously served as senior vice president of research and pre-clinical development at Portola Pharmaceuticals, where she led development of Andexxa, an antidote for blood thinners. She brings expertise in cardiovascular disease and regulatory approvals.PR NewswireCellphire Therapeutics Appoints Pamela B. Conley to its Board of DirectorsCellphire Therapeutics announced the appointment of Dr. Pamela B. Conley to its Board of Directors on February 8, 2022. Dr. Conley brings extensive experience in drug development and regulatory affairs from her previous role at Portola Pharmaceuticals, where she contributed to the approval of Andexxa®. This addition aims to support Cellphire's development of next-generation allogeneic cellular therapeutics.BioSpaceCellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah ManagementCellphire Therapeutics closed a $15 million Series A round led by Simcah Management. The funding supports two Phase 2 trials of Thrombosomes and Cryopreserved Platelets, with Thrombosomes being the only platelet-based freeze-dried hemostatic agent in clinical trials. The company will appoint a new CEO, with Rafael Jorda as interim.PR NewswireCellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah ManagementCellphire Therapeutics, a Rockville-based biotechnology company, closed a $15 million Series A financing round led by Simcah Management to advance its platelet-based products, including Thrombosomes® (the only freeze-dried hemostatic agent in clinical trials) and Cryopreserved Platelets being developed for the U.S. Army. The funding round coincided with leadership changes, as CEO Stephen H. Willard stepped down and will be succeeded by a new CEO, with Rafael Jorda serving as interim CEO and joining the Board alongside new directors Thomas I.H. Dubin and Derek E. Woods. The financing will support expansion of clinical trials, continued development of Thrombosomes® (with a 3-year shelf stability), and research in targeted drug delivery, anti-thrombotic reversal, and regenerative medicine.PR NewswireCellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation SyndromeCellphire, a biotechnology company based in Rockville, Maryland, announced on May 14, 2020 that the FDA granted orphan drug designation for its platelet-based freeze-dried hemostatic product Thrombosomes® for treatment of acute radiation syndrome. The designation provides regulatory incentives including tax credits for clinical trials and prescription drug user fee waivers. Thrombosomes can be stored for up to 3 years at ambient temperatures, compared to 5-7 days for traditional blood products, making them suitable for national emergency preparedness stockpiling.PR NewswireCellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based HemostaticBARDA has exercised its third contract option worth $33.3 million to fund Cellphire's Phase 2 clinical trial of Thrombosomes, a freeze-dried platelet-based hemostatic product, in bleeding thrombocytopenic patients. The funding also supports manufacturing scale-up and pre-clinical studies for a potential additional IND application targeting surgical bleeding. The product addresses critical limitations of standard liquid platelets, which have only a 5- to 7-day shelf life, whereas Thrombosomes offer a 3-year shelf life suitable for national stockpile and disaster response scenarios.